Alaxia Joins iABC to Speed Development of ALX-009, Potential Antibiotic for Resistant Lung Infections

Alaxia has joined the European consortium iABC to accelerate the development of ALX-009, an investigational inhaled antibiotic for multi-drug resistant lung infections in people with cystic fibrosis (CF). Under the partnership, Alaxia will have support for setting up clinical trials and recruiting patients, and will gain access…

CF Foundation Gives Alaxia $1.7M to Start Testing an Inhaled Antimicrobial Therapy in People

Alaxia SAS announced that it has received $1.7 million from the Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development arm of the Cystic Fibrosis Foundation (CFF), to support and advance a first clinical study of its inhaled antimicrobial drug candidate, ALX-009, as a therapy for people with cystic fibrosis…